Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-5,308
Closed -$494K 856
2026
Q1
$494K Sell
5,308
-608
-10% -$53.8K ﹤0.01% 692
2025
Q4
$475K Buy
5,916
+403
+7% +$33.7K ﹤0.01% 803
2025
Q3
$538K Sell
5,513
-2,017
-27% -$162K ﹤0.01% 706
2025
Q2
$525K Sell
7,530
-2,659
-26% -$152K ﹤0.01% 704
2025
Q1
$506K Buy
10,189
+2,057
+25% +$130K ﹤0.01% 795
2024
Q4
$568K Buy
8,132
+1,877
+30% +$156K ﹤0.01% 759
2024
Q3
$656K Buy
6,255
+1,050
+20% +$123K ﹤0.01% 741
2024
Q2
$740K Sell
5,205
-486
-9% -$56K ﹤0.01% 673
2024
Q1
$635K Buy
5,691
+973
+21% +$116K ﹤0.01% 810
2023
Q4
$612K Buy
+4,718
New +$650K ﹤0.01% 832
2023
Q3
Sell
-8,918
Closed -$1.63M 966
2023
Q2
$1.63M Sell
8,918
-2,415
-21% -$348K 0.01% 653
2023
Q1
$1.51M Sell
11,333
-1,380
-11% -$162K 0.01% 723
2022
Q4
$1.01M Sell
12,713
-11,922
-48% -$840K 0.01% 814
2022
Q3
$1.49M Buy
+24,635
New +$1.59M 0.01% 802
2022
Q1
Sell
-27,539
Closed -$2.05M 1059
2021
Q4
$2.05M Buy
+27,539
New +$1.63M 0.01% 863

Other funds holding ACLS

Aviva's ACLS Position: Q2 2026 in Review

Aviva sold out of Axcelis (ACLS) in Q2 2026, closing a stake of 5,308 shares — an estimated $494K sold.

Aviva first reported a position in ACLS in Q4 2021 and held it in 15 quarters. The position peaked at $2.05M in Q4 2021. 441 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • Aviva reported no remaining Axcelis position as of Q2 2026 after selling out during the quarter.
  • Aviva sold 5,308 Axcelis shares in Q2 2026, an estimated $494K.
  • Aviva first reported a position in Axcelis in Q4 2021 and held it in 15 quarters.
  • Aviva's Axcelis position peaked at $2.05M in Q4 2021.
  • 441 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.